Search

Almirall SA

Aperta

SettoreSettore sanitario

12.9 -0.15

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.82

Massimo

12.92

Metriche Chiave

By Trading Economics

Entrata

13M

21M

Vendite

-14M

260M

P/E

Media del settore

60.7

88.032

EPS

0.1

Margine di Profitto

8.059

Dipendenti

2,026

EBITDA

12M

66M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+7.75% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-80M

2.6B

Apertura precedente

13.05

Chiusura precedente

12.9

Notizie sul Sentiment di mercato

By Acuity

34%

66%

88 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Almirall SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 dic 2025, 22:20 UTC

I principali Market Mover

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dic 2025, 17:31 UTC

I principali Market Mover

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dic 2025, 16:30 UTC

I principali Market Mover

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dic 2025, 15:19 UTC

I principali Market Mover

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dic 2025, 15:17 UTC

I principali Market Mover

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dic 2025, 14:37 UTC

I principali Market Mover

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

31 dic 2025, 21:13 UTC

Acquisizioni, Fusioni, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dic 2025, 20:40 UTC

Discorsi di Mercato

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dic 2025, 20:22 UTC

Discorsi di Mercato

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dic 2025, 19:50 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dic 2025, 19:31 UTC

Discorsi di Mercato

Precious Metals Cap Off Record Runs -- Market Talk

31 dic 2025, 18:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

31 dic 2025, 18:50 UTC

Discorsi di Mercato

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dic 2025, 17:17 UTC

Discorsi di Mercato

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dic 2025, 17:16 UTC

I principali Market Mover

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

31 dic 2025, 17:00 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dic 2025, 15:57 UTC

Acquisizioni, Fusioni, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dic 2025, 15:54 UTC

Discorsi di Mercato

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dic 2025, 15:02 UTC

I principali Market Mover

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dic 2025, 14:40 UTC

Acquisizioni, Fusioni, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dic 2025, 14:20 UTC

Discorsi di Mercato

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dic 2025, 13:46 UTC

Discorsi di Mercato

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dic 2025, 13:01 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dic 2025, 11:10 UTC

Discorsi di Mercato

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dic 2025, 10:46 UTC

Discorsi di Mercato

Euro on Track For Strong Annual Performance -- Market Talk

31 dic 2025, 10:25 UTC

Discorsi di Mercato

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dic 2025, 10:23 UTC

Discorsi di Mercato

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dic 2025, 09:33 UTC

Discorsi di Mercato

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Almirall SA Previsione

Obiettivo di Prezzo

By TipRanks

7.75% in crescita

Previsioni per 12 mesi

Media 13.9 EUR  7.75%

Alto 14.5 EUR

Basso 13.3 EUR

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Almirall SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.76 / 10.2Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

88 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat